But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.